Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Flu vaccine showdown: 2023 vs 2024 formula tested in small study

NCT ID NCT06567860

Knowledge-focused Sponsor: La Jolla Institute for Immunology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the 2023 and 2024 flu vaccines protect against influenza A. Researchers gave the 2023 vaccine to 23 healthy adults between May and June 2024, when the vaccine was about to expire, to compare their immune responses with people who got the 2023 vaccine earlier or the 2024 vaccine later. The goal was to understand how updating the vaccine each year affects protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

23 people

The number who actually took part.

Started

May 2024

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be between 18-64 years of age * Males or non-pregnant, non-nursing females * Weigh at least 85 pounds for whole blood draw * Ability to provide signed informed consent * Subjects must plan to receive the intramuscular influenza vaccine at the La Jolla Institute for Immunology Exclusion Criteria: * Received an influenza vaccine in the past year * Infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus * History of certain anemias * Presence of significant cardiovascular disease, systemic diseases including, but not limited to, diabetes which is not controlled, renal disease, liver disease, malignancy, infection, or blood clotting disorder * Inability to provide informed consent * Recent whole blood donation within 56 days or leukapheresis within 112 days * Children (under 18 years of age), elderly (65 years of age or older), pregnant or nursing females * Individuals with egg allergies * Has ever had Guillain-Barré syndrome

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

swine influenza influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza A

Contacts and locations

Locations

  • La Jolla Institute for Immunology

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.